{
  "ticker": "LLY",
  "target_date": "2025-04-29",
  "actual_date": "2025-04-29",
  "collected_at": "2025-12-08T11:42:01.796548",
  "price": {
    "open": 872.7,
    "high": 887.39,
    "low": 869.05,
    "close": 880.1605834960938,
    "volume": 2454400,
    "change_1d_pct": 0.9,
    "change_7d_pct": 5.39,
    "change_30d_pct": 7.33
  },
  "technicals": {
    "rsi_14": 74.27,
    "sma_20": 789.27,
    "sma_50": 829.11,
    "macd": 14.879,
    "macd_signal": -1.59,
    "macd_histogram": 16.469,
    "bb_upper": 904.15,
    "bb_lower": 674.4,
    "price_vs_sma20_pct": 11.52,
    "price_vs_sma50_pct": 6.16,
    "volume_ratio": 0.61
  },
  "fundamentals": {
    "market_cap": 890145734656,
    "pe_ratio": 48.65066,
    "forward_pe": 43.81995,
    "price_to_book": 37.385544,
    "price_to_sales": 14.980625,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.7,
    "pct_from_52w_low": 59.18
  },
  "macro": {
    "spy": {
      "price": 551.16,
      "change_1d_pct": 0.63,
      "change_7d_pct": 7.87
    },
    "vix": {
      "level": 24.17,
      "signal": "ELEVATED"
    },
    "treasury_10y": {
      "yield_pct": 4.17
    },
    "dollar_index": {
      "level": 99.24
    },
    "gold": {
      "price": 3318.8
    },
    "regime": "SIDEWAYS"
  },
  "news": [
    {
      "headline": "Hims & Hers Stock Surges on Wegovy Deal With Novo Nordisk",
      "source": "Yahoo",
      "datetime": 1745944594,
      "summary": "Shares of online health platform Hims & Hers Health soared Tuesday after the company announced a partnership with Novo Nordisk to bring weight-loss drug Wegovy to its customers.",
      "url": "https://finnhub.io/api/news?id=a2e6c2c7604e49d71feb45c71fab024ef8a85fd7e736cd1de734f9d708b34134"
    },
    {
      "headline": "Hims & Hers Health: GLP-1 Deals De-Risk The Story",
      "source": "SeekingAlpha",
      "datetime": 1745940441,
      "summary": "Hims & Hers Health partners with Novo Nordisk (NVO) to offer Wegovy, boosting weight-loss solutions. See why I remain ultra-bullish on HIMS stock.",
      "url": "https://finnhub.io/api/news?id=f878f678c3a10262262c53a6657b437390bfc85b349bdca63561034ea1dccceb"
    },
    {
      "headline": "INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales",
      "source": "Yahoo",
      "datetime": 1745939040,
      "summary": "Incyte reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.",
      "url": "https://finnhub.io/api/news?id=edf8d4cae7db25079583e7167de26e51f339b1de40e3bef0c7f45b0e936dbdf3"
    },
    {
      "headline": "Pfizer offers 'longer-term' opportunity amid tariff uncertainty",
      "source": "Yahoo",
      "datetime": 1745937075,
      "summary": "Pfizer's (PFE) first quarter earnings were mixed, with sales coming in narrowly below Wall Street expectations. The pharmaceutical company has reaffirmed its 2025 outlook and announced plans for $1.2 billion in cost-cutting efforts, though the company says it's \"unable to predict\" the impact of US P",
      "url": "https://finnhub.io/api/news?id=2e945d0fac06e36b13b4dcbafdc3f0063d9e730ce510745adfbe44a2580cad55"
    },
    {
      "headline": "Growth Is Priced Out Of Novo Nordisk",
      "source": "SeekingAlpha",
      "datetime": 1745936975,
      "summary": "Novo Nordisk A/S faces challenges in the obesity market, but new trials and innovations offer hope. Read more on NVO stock prospects.",
      "url": "https://finnhub.io/api/news?id=3e3a2729b24fe4a72743ed23043f06f8ca2747b853450d9356a6e7de8c6aae8e"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-04-22",
      "description": "xslF345X05/wk-form4_1745353361.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000124/xslF345X05/wk-form4_1745353361.xml"
    },
    {
      "form": "4",
      "date": "2025-04-22",
      "description": "xslF345X05/wk-form4_1745353273.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000122/xslF345X05/wk-form4_1745353273.xml"
    },
    {
      "form": "4",
      "date": "2025-04-22",
      "description": "xslF345X05/wk-form4_1745353160.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000120/xslF345X05/wk-form4_1745353160.xml"
    },
    {
      "form": "4",
      "date": "2025-04-22",
      "description": "xslF345X05/wk-form4_1745352964.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000118/xslF345X05/wk-form4_1745352964.xml"
    },
    {
      "form": "4",
      "date": "2025-04-22",
      "description": "xslF345X05/wk-form4_1745352850.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000116/xslF345X05/wk-form4_1745352850.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}